This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
GEHC Unifies bkActiv With Stealth AXiS for Live Neurosurgery Imaging
by Zacks Equity Research
GE HealthCare teams with Medtronic to integrate real-time imaging in cranial surgery, aiming to enhance precision, workflows and clinician decision-making.
MDTNegative Net Change PACBNegative Net Change PAHCNegative Net Change GEHCPositive Net Change
medical medical-devices
Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar
by Zacks Equity Research
SLP beats fiscal Q2 earnings and posts solid revenue growth, but cuts full-year EPS view even as backlog rises and margins expand across software and services.
ADSKNegative Net Change SLPPositive Net Change GWRENegative Net Change BBPositive Net Change
artificial-intelligence computers earnings medical medical-devices tech-stocks
ISRG Stock Down Nearly 20% YTD: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
ISRG slides nearly 20% YTD despite strong procedure growth and upgrades, as valuation concerns and macro pressures weigh on near-term upside.
MDTNegative Net Change SYKNo Net Change ISRGNegative Net Change
medical medical-devices
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
AURAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NEOG Q3 Earnings & Revenues Top, Gross Margin Down, Stock Crashes
by Zacks Equity Research
Neogen beats Q3 earnings and revenue estimates, but margins slump and stock drops nearly 3% after results.
IDXXNegative Net Change NEOGNegative Net Change GMEDNegative Net Change PAHCNegative Net Change
earnings medical medical-devices
AUNA Climbs 21.5% YTD, Outperforms Industry: How to Play the Stock?
by Moumi Mondal
AUNA S.A. rallies as Peru delivers steady growth, Mexico shows turnaround signs, and improved liquidity and cash flow boost confidence in its outlook.
THCNegative Net Change AUNANegative Net Change ARDTNegative Net Change
medical medical-devices
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
by Zacks Equity Research
DVA rides on EPS growth and early IKC profitability, but flat treatment volumes and reimbursement risks raise questions about sustaining momentum.
DVANegative Net Change GMEDNegative Net Change PACBNegative Net Change BDSXNegative Net Change
medical medical-devices
Can 13-15% Procedure Growth in 2026 Sustain ISRG's Premium Valuation?
by Indrajit Bandyopadhyay
Intuitive Surgical's 13-15% 2026 procedure growth signals durable demand and global expansion, but macro and policy risks could test its premium valuation.
SYKNo Net Change ISRGNegative Net Change ZBHPositive Net Change
medical medical-devices
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
by Zacks Equity Research
CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.
PAHCNegative Net Change INSPNegative Net Change CLOVPositive Net Change GEHCPositive Net Change
medical medical-devices
BD Files for CE Mark of Liverty TIPS Stent for Portal Hypertension
by Zacks Equity Research
BDX seeks CE Mark for its Liverty TIPS Stent Graft, a next-gen device aimed at improving portal hypertension treatment and expanding its European footprint.
BDXNegative Net Change PACBNegative Net Change PAHCNegative Net Change GEHCPositive Net Change
medical medical-devices